SCHEDULE: Baker Bros. Boosts Kymera Stake in Public Offering
Schedule 13D Amendment
Baker Bros. Advisors LP and its affiliates increased their beneficial ownership in Kymera Therapeutics, Inc. to 10.9% by participating in a recent public offering.
Summary
- Baker Bros. Advisors LP, Baker Bros. Advisors (GP) LLC, Julian C. Baker, and Felix J. Baker (collectively, the "Reporting Persons") filed an Amendment No. 3 to their Schedule 13D regarding their beneficial ownership in Kymera Therapeutics, Inc.
- The Reporting Persons now beneficially own an aggregate of 8,676,797 shares of Kymera Therapeutics, Inc. common stock, representing 10.9% of the class.
- This increase in ownership resulted from the participation of Baker Brothers Life Sciences, L.P. and 667, L.P. (the "Funds"), managed by Baker Bros. Advisors LP, in Kymera's public offering.
- Kymera Therapeutics, Inc. entered into an underwriting agreement on December 9, 2025, for a public offering of 7,000,000 shares of common stock at $86.00 per share.
- The underwriters exercised their option to purchase an additional 1,050,000 shares to cover overallotments in full on December 10, 2025, bringing the total offering to 8,050,000 shares.
- The offering closed on December 11, 2025.
- The Funds purchased a total of 2,005,813 shares of common stock in the offering at $86.00 per share (167,192 shares by 667, L.P. and 1,838,621 shares by Baker Brothers Life Sciences, L.P.) using their working capital.
- The percentage of beneficial ownership is based on 78,741,174 shares outstanding as of December 11, 2025, plus the 1,050,000 shares from the underwriters' option exercise, and 19,555 vested non-qualified stock options held by Felix J. Baker.
- The Funds also hold 11,200,154 prefunded warrants, exercisable at $0.0001 per share, but these are not currently exercisable due to a 4.99% beneficial ownership limitation, which can be increased to 19.99% with 61 days' notice.
- Felix J. Baker, a managing member of Baker Bros. Advisors (GP) LLC, serves on Kymera's Board of Directors and Compensation Committee and holds stock options (32,000 at $40.20/share, 16,000 at $46.47/share). His director compensation's pecuniary interest is directed to the Funds.
Sentiment
Score: 7
Explanation: The filing is primarily a factual disclosure of an investment. The participation of a significant, specialized biotech investor like Baker Bros. in Kymera's public offering is generally viewed as a positive signal of confidence in the company's future, hence a moderately positive score.
Positives
- Baker Bros. Advisors LP and its affiliates, a prominent biotech investor, increased their stake in Kymera Therapeutics, Inc., signaling continued confidence in the company's prospects.
- Kymera Therapeutics successfully completed a public offering, raising capital for its operations.
- The underwriters fully exercised their overallotment option, indicating strong demand for the offering.
Risks
- The prefunded warrants held by the Funds, totaling 11,200,154, are not currently exercisable due to a 4.99% beneficial ownership limitation, restricting immediate conversion into common stock.
- The Reporting Persons may purchase additional securities or dispose of securities in varying amounts and at varying times, which could impact the stock price.
Future Outlook
The Reporting Persons hold securities for investment purposes and may purchase additional securities or dispose of existing holdings in varying amounts and at varying times. These decisions will depend on their ongoing assessment of pertinent factors, including the Issuer's business prospects, economic conditions, market conditions, and other investment opportunities. They may also engage in discussions with Kymera's management and board regarding financing or other strategic matters.
Industry Context
The participation of Baker Bros. Advisors, a highly respected and specialized investor in the biotechnology sector, in Kymera Therapeutics' public offering is a significant signal of confidence. This investment suggests that a key industry player sees value and potential in Kymera's pipeline and strategic direction, which can be a positive indicator for other investors in the competitive biotech landscape.
Comparison to Industry Standards
- Baker Bros. Advisors is a well-known institutional investor in the biotech space, often taking significant stakes in companies they believe have strong potential. Their 10.9% stake in Kymera Therapeutics is a substantial position, comparable to other significant investments they hold in emerging and established biotech firms.
- The public offering price of $86.00 per share and the total capital raised reflect market conditions and investor appetite for biotech companies with promising pipelines, similar to other recent capital raises in the sector, though specific comparable projects or companies are not detailed in this filing.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Director, Compensation Committee Member | N/A (no change reported) | Felix J. Baker | N/A (existing role) | N/A (no change reported) |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Director Compensation Policy | The policies of the Funds and the Adviser do not permit managing members of the Adviser GP (like Felix J. Baker) to receive compensation for serving as a director of the Issuer; instead, the Funds are entitled to the pecuniary interest in any such compensation. | N/A (existing policy) | Aligns director incentives with the interests of the Funds, potentially reducing conflicts of interest for the individual director. |
| Lock-Up Agreement | Felix J. Baker entered into a Director Lock-Up Agreement, restricting his ability to sell or transfer Kymera common stock or related securities from December 9, 2025, to February 7, 2026. | December 9, 2025 | Standard practice in public offerings to prevent immediate selling pressure from insiders, demonstrating commitment and stability post-offering. |
Related Party Transactions
- Baker Brothers Life Sciences, L.P. and 667, L.P., which are managed by Baker Bros. Advisors LP (a Reporting Person), purchased 2,005,813 shares of Kymera Therapeutics, Inc. common stock in the public offering at $86.00 per share.
- Felix J. Baker, a managing member of Baker Bros. Advisors (GP) LLC and a director of Kymera, holds stock options in Kymera. The pecuniary interest in his director compensation is directed to the Funds managed by Baker Bros. Advisors LP.
Stakeholder Impact
- Shareholders: The public offering resulted in dilution for existing shareholders due to the issuance of new shares, but also provided Kymera with additional capital for operations. The continued significant investment by Baker Bros. may be viewed positively.
- Kymera Therapeutics, Inc.: The company successfully raised substantial capital through the public offering, which can be used to fund research, development, and other strategic initiatives.
- Employees: Increased capital could support ongoing operations and potential growth, indirectly benefiting employees through job security and opportunities.
Next Steps
- The Reporting Persons may purchase additional securities or dispose of securities of Kymera Therapeutics, Inc. in the future.
- The Reporting Persons may engage in discussions with Kymera's management and board regarding financing, acquisitions, or other strategic matters.
- The Funds may increase the beneficial ownership limitation on their prefunded warrants to up to 19.99% by providing 61 days' written notice to the Issuer.
Key Dates
| Date | Description |
|---|---|
| March 28, 2024 | Commencement of vesting for 32,000 stock options held by Felix J. Baker, vesting in 36 equal monthly installments over three years. |
| December 9, 2025 | Kymera Therapeutics, Inc. entered into an underwriting agreement for a public offering; Felix J. Baker entered into a Director Lock-Up Agreement. |
| December 10, 2025 | Underwriters exercised their option to purchase an additional 1,050,000 shares in full; Kymera's Prospectus filed with the SEC. |
| December 11, 2025 | The public offering closed; Date of filing signature for the Schedule 13D Amendment No. 3. |
| February 7, 2026 | End date of the Director Lock-Up Agreement for Felix J. Baker. |
| 2026 annual meeting | Earlier vesting condition for 16,000 stock options held by Felix J. Baker. |
| March 27, 2034 | Expiration date for 32,000 stock options held by Felix J. Baker. |
Keywords
Kymera Therapeutics, Baker Bros. Advisors, Schedule 13D, Public Offering, Common Stock, Biotechnology, Investment, Shareholding, SEC Filing, Underwriting Agreement, Prefunded Warrants
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.